SEPTInvestingStart Free
Stocks/DTIL/SEC Filings/8-K Nov 6, 2026

DTIL 8-K: Secondary offering

Filed with the SEC on Nov 6, 2026 · accession 0001628280-26-071304

DTIL filed a 8-K (current report) with the SEC on Nov 6, 2026. Precision BioSciences priced an underwritten public offering of 10,235,077 shares of common stock at $7.75 per share plus pre-funded warrants to purchase up to 5,893,964 shares at $7.749995 per warrant, expecting approximately $116.5 million in net proceeds.

Summary of the filing

Precision BioSciences priced an underwritten public offering of 10,235,077 shares of common stock at $7.75 per share plus pre-funded warrants to purchase up to 5,893,964 shares at $7.749995 per warrant, expecting approximately $116.5 million in net proceeds. Proceeds will fund research and development of PBGENE-HBV and PBGENE-DMD and for working capital and general corporate purposes.

For details, click here →How to read a 8-K →

Key details

Shares of common stock offeredshares 10.2M
Offering price per share of common stock$8
Pre-funded warrants offeredwarrants 5.9M
Offering price per pre-funded warrant$8
Estimated net proceeds$116.5M
IssuerPrecision BioSciences, Inc.
Underwriter representativeTD Securities (USA) LLC
Underwriter representativeGuggenheim Securities, LLC
Counsel to issuerLatham & Watkins LLP

✦ Ask GOAX AI about this filing — what it means for DTIL, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for DTIL?

Click here

Frequently asked questions

What did DTIL file with the SEC on Nov 6, 2026?

DTIL filed a 8-K (Secondary offering). Precision BioSciences priced an underwritten public offering of 10,235,077 shares of common stock at $7.75 per share plus pre-funded warrants to purchase up to 5,893,964 shares at $7.749995 per warrant, expecting approximately $116.5 million in net proceeds. Proceeds will fund research and development of PBGENE-HBV and PBGENE-DMD and for working capital and general corporate purposes.

What does a secondary offering mean for DTIL stock?

New shares dilute existing holders and are often sold at a discount to the market price.

How do I read a 8-K?

A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more. The "Item" number tells you the topic (e.g. 2.02 results, 5.02 executive change, 1.01 new agreement, 1.03 bankruptcy). Exhibits (99.1 press release) usually hold the details.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 8-K (current report): A report of a major event, filed within four business days: results, deals, leadership changes, bankruptcy and more.

Other DTIL SEC filings

  • 424B5 · Secondary offeringNov 6, 2026
  • 8-K · Fda approvalNov 5, 2026
  • 10-Q · SEC filingNov 3, 2026
  • 8-K · SEC filingNov 3, 2026
  • 8-K · SEC filingAug 24, 2026
  • 8-K · SEC filingAug 6, 2026
  • 10-Q · SEC filingAug 6, 2026
  • 8-K · Ceo changeJul 27, 2026
  • 8-K · SEC filingJul 1, 2026
  • 8-K · Material agreementJun 16, 2026

Get alerts when DTIL files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
DTIL overviewDTIL analysisDTIL newsLatest SEC filings
Source: SEC EDGAR filing 0001628280-26-071304. The summary and key details are extracted by SEPT from the filing and may contain errors. Price reaction uses daily closing prices. Not financial advice.